A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

NCT03926130 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1158

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: Mirikizumab
DRUG: Mirikizumab
DRUG: Ustekinumab
DRUG: Ustekinumab
DRUG: Placebo
DRUG: Placebo

Sponsor

Eli Lilly and Company